Medisafe Proves Its Self-Reported Adherence Data Are Consistent with Prescription Refill Claims

New data paves the way for outcomes-driven industry collaborations

LAS VEGAS, NV — March 6, 2018. Medisafe, the leading medication management platform with over four million registered users, announced today the first wave of results from a novel study, which among other objectives, measures the accuracy of self-reported outcomes (SROs). Medisafe’s study was conducted in partnership with the leading global provider of information, innovative technology solutions and contract research services focused on healthcare data. The initial results shine a positive light on the predictive power of self-reported adherence data.

The study methodology entailed mapping users and their self-reported adherence data to their corresponding prescription claims using a HIPAA-compliant, non-identification process. The results show that the medication possession ratio (MPR) for Medisafe users taking antihypertensives and novel oral anticoagulants (NOACs) is on average 7 to 9% higher than the adherence they report on Medisafe. MPR is a standard metric used by the healthcare industry to track adherence based on prescription claims.

Included in the table below is a summary of key findings for the first two medication categories analyzed:

Medication Category

Number
Patients
(N)

Mean Patient
Age (SD)

Self-
Reported
Adherence

MPR
(based
on Rx
claims)

Antihypertensives

7,084

54.32 (11.81)

85%

92%

NOACs

660

58.72 (12.48)

85%

94%

Importantly, the study results are among the first to report the accuracy of patient self-reporting of their medication adherence. A prevailing hypothesis until now has been that self-reporting in healthcare mobile apps is often exaggerated due to alert fatigue or patient “cheating.”

“Historically pharma, payers and the broader care continuum have been skeptical of self-reported data, often dismissing it as biased and inflated. On the contrary, with this study we’ve shown that Medisafe’s self-reported adherence rates are actually lower than industry-standard measures,” says Jon Michaeli, EVP of Strategic Partnerships at Medisafe. “We now have evidence that Medisafe’s adherence data are a trustworthy, insightful complement to traditional data sources. Because we calculate adherence in real-time at the medication dose level, pharma, payers and other industry stakeholders should no longer be in the dark about medication adherence at critical points in the patient journey, when they have a fleeting opportunity to intervene and correct course.”

In the coming months, Medisafe will continue to release results from the landmark study, including data regarding the platform’s impact on patient adherence to a number of different types of medication.

The Medisafe team will be available at HIMSS 2018 at booth #9900-64 in the Innovation Zone to discuss study results. To schedule a meeting please click here.

You may also like

Research

Digital Patient Engagement Data

Get the latest insights from industry leaders on how pharma can capture greater value from digital patient programs. Download the 

..Read More
Infographics

Medisafe’s Digital Companion Launch Toolkit

This free launch toolkit has the must-have answers and best practices for all eight stages of a successful digital  launch. 

..Read More
Webinars

Webinar: The Economic Impact of Digital Companions

The data is in, and savvy pharma execs see that supporting patient engagement is not only a growing strategic initiative 

..Read More

Want to Learn More?

We bring decades of experience to your challenges—and technology and solutions uniquely designed to meet your needs.